Regulation of Proteasome and Cell Cycle By PAGR1 (G79447)

Target Name: PAGR1

NCBI ID: G79447

PAGR1

Regulation of Proteasome and Cell Cycle By PAGR1

PAGR1 (Proteasome-Advanced GTPase Regulatory protein 1) is a protein that is expressed in various tissues throughout the body. It is a key regulator of the proteasome, a protein that helps to break down and remove large proteins from cells. PAGR1 is also involved in the regulation of cell cycle progression and in the maintenance of cellular homeostasis.

PAGR1 is a protein that is expressed in most tissues of the body, including the brain, muscle, heart, and gastrointestinal tract. It is a key regulator of the proteasome, a protein that helps to break down and remove large proteins from cells. The proteasome is a complex protein that is composed of several subunits that work together to carry out various functions in the cell.

PAGR1 is involved in the regulation of the proteasome by interacting with several of its subunits, including the 26S subunit of the proteasome. This interaction between PAGR1 and the 26S subunit allows PAGR1 to regulate the activity of the proteasome and to play a role in the regulation of cellular homeostasis.

PAGR1 is also involved in the regulation of cell cycle progression. It is a component of the G1-protein-coupled receptor (GPCR) signaling pathway, a pathway that is involved in the regulation of cell growth and division. PAGR1 is involved in the regulation of the G1 phase of the cell cycle, which is the phase of the cell cycle when the cell prepares for cell division.

In addition to its role in the regulation of the proteasome and cell cycle progression, PAGR1 is also involved in the maintenance of cellular homeostasis. It is a component of various cellular signaling pathways that help to maintain the stability of cellular environments, including the concentration of oxygen and the levels of pH in the body.

PAGR1 is also a potential drug target. Researchers have identified several potential drug targets for PAGR1, including the inhibition of PAGR1 function and the use of small molecules that can interact with PAGR1. These drug targets are being studied in order to determine the effectiveness of these treatments in a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

Overall, PAGR1 is a protein that is involved in a variety of cellular processes that are important for the maintenance of cellular homeostasis and the regulation of cell cycle progression. It is a potential drug target and may be a useful biomarker for the diagnosis and treatment of a variety of diseases.

Protein Name: PAXIP1 Associated Glutamate Rich Protein 1

Functions: Its association with the histone methyltransferase MLL2/MLL3 complex is suggesting a role in epigenetic transcriptional activation. However, in association with PAXIP1/PTIP is proposed to function at least in part independently of the MLL2/MLL3 complex. Proposed to be recruited by PAXIP1 to sites of DNA damage where the PAGR1:PAXIP1 complex is required for cell survival in response to DNA damage independently of the MLL2/MLL3 complex (PubMed:19124460). However, its function in DNA damage has been questioned (By similarity). During immunoglobulin class switching in activated B-cells is involved in transcription regulation of downstream switch regions at the immunoglobulin heavy-chain (Igh) locus independently of the MLL2/MLL3 complex (By similarity). Involved in both estrogen receptor-regulated gene transcription and estrogen-stimulated G1/S cell-cycle transition (PubMed:19039327). Acts as transcriptional cofactor for nuclear hormone receptors. Inhibits the induction properties of several steroid receptors such as NR3C1, AR and PPARG; the mechanism of inhibition appears to be gene-dependent (PubMed:23161582)

The "PAGR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PAGR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets